Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study.

Fauchier L, Blin P, Sacher F, Dureau-Pournin C, Bernard MA, Lassalle R, Droz-Perroteau C, Dallongeville J, Moore N.

Europace. 2019 Oct 22. pii: euz285. doi: 10.1093/europace/euz285. [Epub ahead of print]

PMID:
31638652
2.

Pharmacological treatment patterns in heart failure: a population-based cohort study.

Bosco-Lévy P, Favary C, Jové J, Lassalle R, Moore N, Droz-Perroteau C.

Eur J Clin Pharmacol. 2019 Oct 21. doi: 10.1007/s00228-019-02758-2. [Epub ahead of print]

PMID:
31637454
3.

Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation.

Blin P, Fauchier L, Dureau-Pournin C, Sacher F, Dallongeville J, Bernard MA, Lassalle R, Droz-Perroteau C, Moore N.

Stroke. 2019 Sep;50(9):2469-2476. doi: 10.1161/STROKEAHA.119.025824. Epub 2019 Aug 8.

4.

Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015): A cross-national drug utilization study.

Ibáñez L, Sabaté M, Vidal X, Ballarin E, Rottenkolber M, Schmiedl S, Heeke A, Huerta C, Martin Merino E, Montero D, Leon-Muñoz LM, Gasse C, Moore N, Droz C, Lassalle R, Aakjaer M, Andersen M, De Bruin ML, Groenwold R, van den Ham HA, Souverein P, Klungel O, Gardarsdottir H.

Br J Clin Pharmacol. 2019 Nov;85(11):2524-2539. doi: 10.1111/bcp.14071. Epub 2019 Sep 4.

5.

Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS.

Blin P, Dureau-Pournin C, Bénichou J, Cottin Y, Mismetti P, Abouelfath A, Lassalle R, Droz C, Moore N.

Am J Cardiovasc Drugs. 2019 Jun 29. doi: 10.1007/s40256-019-00359-z. [Epub ahead of print]

PMID:
31254174
6.

Bismuth Concentrations in Patients Treated in Real-Life Practice with a Bismuth Subcitrate-Metronidazole-Tetracycline Preparation: The SAPHARY Study.

Guiard E, Lelievre B, Rouyer M, Zerbib F, Diquet B, Mégraud F, Tison F, Bignon E, Lassalle R, Droz-Perroteau C, Moore N, Blin P.

Drug Saf. 2019 Aug;42(8):993-1003. doi: 10.1007/s40264-019-00821-6.

PMID:
31069703
7.

Monitoring of drug misuse or potential misuse in a nationwide healthcare insurance database: A cross-sectional study in France.

Bénard-Laribière A, Noize P, Girodet PO, Lassalle R, Dureau-Pournin C, Droz-Perroteau C, Fourrier-Réglat A, Salvo F, Bezin J, Pariente A; DRUGS-2M study group.

Therapie. 2019 Sep;74(4):469-476. doi: 10.1016/j.therap.2018.12.007. Epub 2018 Dec 30.

PMID:
30857740
8.

Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.

Blin P, Dureau-Pournin C, Benichou J, Bonello L, Dallongeville J, Danchin N, Falissard B, Thomas-Delecourt F, Jové J, Lassalle R, Droz C, Moore N.

Atherosclerosis. 2019 Feb;281:98-106. doi: 10.1016/j.atherosclerosis.2018.11.037. Epub 2018 Dec 7.

PMID:
30658197
9.

Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study.

Gouverneur A, Coutureau J, Jové J, Rouyer M, Grelaud A, Duc S, Gérard S, Smith D, Ravaud A, Droz C, Bernard MA, Lassalle R, Forrier-Réglat A, Noize P; ETNA study group and the EREBUS study group.

Clin Colorectal Cancer. 2019 Mar;18(1):e150-e162. doi: 10.1016/j.clcc.2018.11.005. Epub 2018 Nov 29.

PMID:
30630730
10.

Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: A nationwide database cohort study.

Blin P, Samama CM, Sautet A, Benichou J, Lignot-Maleyran S, Lamarque S, Lorrain S, Lassalle R, Droz-Perroteau C, Mismetti P, Moore N.

Pharmacol Res. 2019 Mar;141:201-207. doi: 10.1016/j.phrs.2018.12.018. Epub 2018 Dec 21.

PMID:
30583081
11.

Use of benzodiazepines and z-drugs not compliant with guidelines and associated factors: a population-based study.

Panes A, Pariente A, Bénard-Laribière A, Lassalle R, Dureau-Pournin C, Lorrain S, Tournier M, Fourrier-Réglat A.

Eur Arch Psychiatry Clin Neurosci. 2018 Dec 11. doi: 10.1007/s00406-018-0966-3. [Epub ahead of print]

PMID:
30539229
12.

Comparative Effectiveness and Safety of Standard or Reduced Dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial Fibrillation.

Blin P, Dureau-Pournin C, Cottin Y, Bénichou J, Mismetti P, Abouelfath A, Lassalle R, Droz C, Moore N.

Clin Pharmacol Ther. 2019 Jun;105(6):1439-1455. doi: 10.1002/cpt.1318. Epub 2019 Feb 6.

PMID:
30499605
13.

Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation.

Blin P, Dureau-Pournin C, Cottin Y, Bénichou J, Mismetti P, Abouelfath A, Lassalle R, Droz C, Moore N.

Br J Clin Pharmacol. 2019 Feb;85(2):432-441. doi: 10.1111/bcp.13815. Epub 2018 Dec 16.

PMID:
30423205
14.

Previous Drug Exposure in Patients Hospitalised for Acute Liver Injury: A Case-Population Study in the French National Healthcare Data System.

Moore N, Duret S, Grolleau A, Lassalle R, Barbet V, Duong M, Thurin N, Droz-Perroteau C, Gulmez SE.

Drug Saf. 2019 Apr;42(4):559-572. doi: 10.1007/s40264-018-0752-1.

15.

An observational cohort study of the use of five-grass-pollen extract sublingual immunotherapy during the 2015 pollen season in France.

Blin P, Demoly P, Drouet M, Falissard B, Lignot-Maleyran S, Maizi H, Lorrain S, Lassalle R, Droz-Perroteau C, Moore N, Molimard M.

Allergy Asthma Clin Immunol. 2018 Sep 24;14:38. doi: 10.1186/s13223-018-0262-9. eCollection 2018.

16.

Risk of hospital admission for liver injury in users of NSAIDs and nonoverdose paracetamol: Preliminary results from the EPIHAM study.

Gulmez SE, Unal US, Lassalle R, Chartier A, Grolleau A, Moore N.

Pharmacoepidemiol Drug Saf. 2018 Nov;27(11):1174-1181. doi: 10.1002/pds.4640. Epub 2018 Aug 16.

17.

Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample.

Duong M, Abouelfath A, Lassalle R, Droz C, Blin P, Moore N.

Drug Saf. 2018 Nov;41(11):1049-1058. doi: 10.1007/s40264-018-0686-7.

PMID:
29797240
18.

Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS Cohort.

Rouyer M, François E, Cunha AS, Monnereau A, Noize P, Robinson P, Droz-Perroteau C, Le Monies de Sagazan A, Jové J, Lassalle R, Moore N, Fourrier-Réglat A, Smith D; EREBUS Study Group.

Clin Colorectal Cancer. 2018 Jun;17(2):129-139. doi: 10.1016/j.clcc.2018.01.007. Epub 2018 Jan 31.

PMID:
29523416
19.

Medications Recommended for Secondary Prevention After First Acute Coronary Syndrome: Effectiveness of Treatment Combinations in a Real-Life Setting.

Bezin J, Klungel OH, Lassalle R, Dureau-Pournin C, Moore N, Pariente A.

Clin Pharmacol Ther. 2018 Jun;103(6):1038-1046. doi: 10.1002/cpt.864. Epub 2017 Sep 28.

PMID:
28875506
20.

Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.

Noize P, Grelaud A, Bay JO, Chevreau C, Gross-Goupil M, Culine S, Ferrière JM, Moulin F, Robinson P, Balestra A, Lamarque S, Bernard MA, Lassalle R, Rouyer M, Droz-Perroteau C, Moore N, Fourrier-Réglat A, Ravaud A.

Pharmacoepidemiol Drug Saf. 2017 Dec;26(12):1561-1569. doi: 10.1002/pds.4228. Epub 2017 Jun 1.

PMID:
28573786
21.

The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology.

Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, Moore N.

Pharmacoepidemiol Drug Saf. 2017 Aug;26(8):954-962. doi: 10.1002/pds.4233. Epub 2017 May 24.

PMID:
28544284
22.

Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims database.

Blin P, Dureau-Pournin C, Lassalle R, Jové J, Thomas-Delecourt F, Droz-Perroteau C, Danchin N, Moore N.

Br J Clin Pharmacol. 2017 Sep;83(9):2056-2065. doi: 10.1111/bcp.13291. Epub 2017 May 5.

23.

Type 2 Diabetes Mellitus Treatment Patterns Across Europe: A Population-based Multi-database Study.

Overbeek JA, Heintjes EM, Prieto-Alhambra D, Blin P, Lassalle R, Hall GC, Lapi F, Bianchini E, Hammar N, Bezemer ID, Herings RMC.

Clin Ther. 2017 Apr;39(4):759-770. doi: 10.1016/j.clinthera.2017.02.008. Epub 2017 Mar 23.

PMID:
28342563
24.

Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients.

Molimard M, Raherison C, Lignot S, Balestra A, Lamarque S, Chartier A, Droz-Perroteau C, Lassalle R, Moore N, Girodet PO.

Eur Respir J. 2017 Feb 15;49(2). pii: 1601794. doi: 10.1183/13993003.01794-2016. Print 2017 Feb.

25.

Comparative effectiveness of recommended versus less intensive drug combinations in secondary prevention of acute coronary syndrome.

Bezin J, Groenwold RH, Ali MS, Lassalle R, Robinson P, de Boer A, Moore N, Klungel OH, Pariente A.

Pharmacoepidemiol Drug Saf. 2017 Mar;26(3):285-293. doi: 10.1002/pds.4171. Epub 2017 Jan 26.

PMID:
28124399
26.

Usage patterns of paracetamol in France.

Duong M, Gulmez SE, Salvo F, Abouelfath A, Lassalle R, Droz C, Blin P, Moore N.

Br J Clin Pharmacol. 2016 Aug;82(2):498-503. doi: 10.1111/bcp.12957. Epub 2016 May 18.

27.

Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting.

Bouchet S, Poulette S, Titier K, Moore N, Lassalle R, Abouelfath A, Italiano A, Chevreau C, Bompas E, Collard O, Duffaud F, Rios M, Cupissol D, Adenis A, Ray-Coquard I, Bouché O, Le Cesne A, Bui B, Blay JY, Molimard M.

Eur J Cancer. 2016 Apr;57:31-8. doi: 10.1016/j.ejca.2015.12.029. Epub 2016 Feb 4.

PMID:
26851399
28.

Bronchial Smooth Muscle Remodeling in Nonsevere Asthma.

Girodet PO, Allard B, Thumerel M, Begueret H, Dupin I, Ousova O, Lassalle R, Maurat E, Ozier A, Trian T, Marthan R, Berger P.

Am J Respir Crit Care Med. 2016 Mar 15;193(6):627-33. doi: 10.1164/rccm.201507-1404OC.

PMID:
26540234
29.

A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC.

Blin P, Dureau-Pournin C, Lassalle R, Abouelfath A, Droz-Perroteau C, Moore N.

Br J Clin Pharmacol. 2016 Mar;81(3):569-78. doi: 10.1111/bcp.12807. Epub 2015 Dec 28.

30.

Effect of Centaurium erythraea Rafn, Artemisia herba-alba Asso and Trigonella foenum-graecum L. on liver fat accumulation in C57BL/6J mice with high-fat diet-induced type 2 diabetes.

Hamza N, Berke B, Cheze C, Marais S, Lorrain S, Abdouelfath A, Lassalle R, Carles D, Gin H, Moore N.

J Ethnopharmacol. 2015 Aug 2;171:4-11. doi: 10.1016/j.jep.2015.05.027. Epub 2015 May 25.

PMID:
26023031
31.

Liver transplant associated with paracetamol overdose: results from the seven-country SALT study.

Gulmez SE, Larrey D, Pageaux GP, Bernuau J, Bissoli F, Horsmans Y, Thorburn D, McCormick PA, Stricker B, Toussi M, Lignot-Maleyran S, Micon S, Hamoud F, Lassalle R, Jové J, Blin P, Moore N.

Br J Clin Pharmacol. 2015 Sep;80(3):599-606. doi: 10.1111/bcp.12635. Epub 2015 May 27.

32.

Drug use in French children: a population-based study.

Bénard-Laribière A, Jové J, Lassalle R, Robinson P, Droz-Perroteau C, Noize P.

Arch Dis Child. 2015 Oct;100(10):960-5. doi: 10.1136/archdischild-2014-307224. Epub 2015 May 14.

PMID:
25977563
33.

Burnout: evaluation of the efficacy and tolerability of TARGET 1® for professional fatigue syndrome (burnout).

Jacquet A, Grolleau A, Jove J, Lassalle R, Moore N.

J Int Med Res. 2015 Feb;43(1):54-66. doi: 10.1177/0300060514558324. Epub 2014 Dec 23.

PMID:
25537278
34.

Parkinson's disease incidence and prevalence assessment in France using the national healthcare insurance database.

Blin P, Dureau-Pournin C, Foubert-Samier A, Grolleau A, Corbillon E, Jové J, Lassalle R, Robinson P, Poutignat N, Droz-Perroteau C, Moore N.

Eur J Neurol. 2015 Mar;22(3):464-71. doi: 10.1111/ene.12592. Epub 2014 Nov 12.

PMID:
25389031
35.

Misuse, Abuse, and Diversion of instanyl® (Fentanyl Nasal Spray) in France.

Blin P, Dureau C, Lamarque S, Bernard MA, Robinson P, Lassalle R, Grolleau A, Droz C, Moore N.

Value Health. 2014 Nov;17(7):A649. doi: 10.1016/j.jval.2014.08.2357. Epub 2014 Oct 26. No abstract available.

36.

[Decision process in a multidisciplinary cancer team with limited evidence].

Lassalle R, Marold J, Schöbel M, Manzey D, Bohn S, Dietz A, Boehm A.

Laryngorhinootologie. 2014 Apr;93(4):237-43. doi: 10.1055/s-0033-1353199. Epub 2013 Dec 10. German.

PMID:
24327352
37.

Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France.

Bezin J, Pariente A, Lassalle R, Dureau-Pournin C, Abouelfath A, Robinson P, Moore N, Droz-Perroteau C, Fourrier-Reglat A.

Eur J Clin Pharmacol. 2014 Apr;70(4):429-36. doi: 10.1007/s00228-013-1614-5. Epub 2013 Nov 24.

PMID:
24271648
38.

Usage patterns of 'over-the-counter' vs. prescription-strength nonsteroidal anti-inflammatory drugs in France.

Duong M, Salvo F, Pariente A, Abouelfath A, Lassalle R, Droz C, Blin P, Moore N.

Br J Clin Pharmacol. 2014 May;77(5):887-95. doi: 10.1111/bcp.12239.

39.

Relative risks from case-population data.

Moore N, Gulmez SE, Blin P, Lassalle R, Jove J, Théophile H, Bégaud B, Larrey D, Bénichou J.

Epidemiology. 2013 Nov;24(6):935-6. doi: 10.1097/EDE.0b013e3182a77882. No abstract available.

PMID:
24076997
40.

Observation of the long-term effects of lifestyle intervention during balneotherapy in metabolic syndrome.

Gin H, Demeaux JL, Grelaud A, Grolleau A, Droz-Perroteau C, Robinson P, Lassalle R, Abouelfath A, Boisseau M, Toussaint C, Moore N.

Therapie. 2013 May-Jun;68(3):163-7. doi: 10.2515/therapie/2013025. Epub 2013 Jul 26.

PMID:
23886461
41.

Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort study.

Fourrier-Réglat A, Noize P, Facon T, Fermand JP, Fitoussi O, Marit G, Thomaré P, Robinson P, Bignon E, Jové J, Lassalle R, Rouyer M, Grelaud A, Moore N; VESUVE Study Group.

Leuk Lymphoma. 2014 Apr;55(4):848-54. doi: 10.3109/10428194.2013.806801. Epub 2013 Aug 28.

PMID:
23808815
42.

Causality of Drugs Involved in Acute Liver Failure Leading to Transplantation: Results from the Study of Acute Liver Transplant (SALT).

Gulmez SE, Moore N, Pageaux GP, Lignot S, Horsmans Y, Stricker B, Bernuau J, Bissoli F, Thorburn D, Montastruc JL, Micon S, Hamoud F, Lassalle R, Jové J, Blin P, Larrey D.

Drug Saf. 2013 Sep;36(9):757-64. doi: 10.1007/s40264-013-0071-5.

PMID:
23743692
43.

Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France.

Guelfucci F, Clay E, Aballéa S, Lassalle R, Moore N, Toumi M.

BMC Endocr Disord. 2013 Apr 29;13:15. doi: 10.1186/1472-6823-13-15.

44.

Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study.

Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jové J, Gatta A, McCormick PA, Metselaar HJ, Monteiro E, Thorburn D, Bernal W, Zouboulis-Vafiadis I, de Vries C, Perez-Gutthann S, Sturkenboom M, Bénichou J, Montastruc JL, Horsmans Y, Salvo F, Hamoud F, Micon S, Droz-Perroteau C, Blin P, Moore N.

Drug Saf. 2013 Feb;36(2):135-44. doi: 10.1007/s40264-012-0013-7.

45.

Choice of the denominator in case population studies: event rates for registration for liver transplantation after exposure to NSAIDs in the SALT study in France.

Moore N, Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jové J, Pariente A, Blin P, Bénichou J, Bégaud B.

Pharmacoepidemiol Drug Saf. 2013 Feb;22(2):160-7. doi: 10.1002/pds.3371. Epub 2012 Nov 20.

PMID:
23166053
46.

Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory.

Bouchet S, Titier K, Moore N, Lassalle R, Ambrosino B, Poulette S, Schuld P, Belanger C, Mahon FX, Molimard M.

Fundam Clin Pharmacol. 2013 Dec;27(6):690-7. doi: 10.1111/fcp.12007. Epub 2012 Oct 31.

PMID:
23113675
47.

Seizure freedom is not adversely affected by early discontinuation of concomitant anti-epileptic drugs in the EULEV cohort of levetiracetam users.

Droz-Perroteau C, Marchal C, Dureau-Pournin C, Lassalle R, Jové J, Robinson P, Lavernhe G, Vespignani H, Moore N, Fourrier-Réglat A; Eulev Study Group.

Pharmacoepidemiol Drug Saf. 2012 Nov;21(11):1183-9. doi: 10.1002/pds.3338. Epub 2012 Sep 13.

PMID:
22972760
48.

Preventive and curative effect of Trigonella foenum-graecum L. seeds in C57BL/6J models of type 2 diabetes induced by high-fat diet.

Hamza N, Berke B, Cheze C, Le Garrec R, Umar A, Agli AN, Lassalle R, Jové J, Gin H, Moore N.

J Ethnopharmacol. 2012 Jul 13;142(2):516-22. doi: 10.1016/j.jep.2012.05.028. Epub 2012 May 23.

PMID:
22633967
49.

Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database.

Blin P, Lassalle R, Dureau-Pournin C, Ambrosino B, Bernard MA, Abouelfath A, Gin H, Le Jeunne C, Pariente A, Droz C, Moore N.

Diabetologia. 2012 Mar;55(3):644-53. doi: 10.1007/s00125-011-2429-5. Epub 2012 Jan 6.

50.

Chemotherapy and targeted agents for colorectal cancer in a real-life setting anticipate guidelines: the COLCHIC cohort study.

Smith D, Terrebonne E, Rouyer M, Blanc JF, Breilh D, Pedeboscq S, Le Monies A, Lecomte C, Lassalle R, Moore N, Fourrier-Réglat A.

Fundam Clin Pharmacol. 2013 Feb;27(1):113-9. doi: 10.1111/j.1472-8206.2011.00961.x. Epub 2011 Jul 27.

PMID:
21793898

Supplemental Content

Loading ...
Support Center